PeterLabs Holdings Bhd
KLSE:PLABS
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.087
0.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches MYR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| MY |
P
|
PeterLabs Holdings Bhd
KLSE:PLABS
|
74.3m MYR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
529.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -51 526.8% |
| 30th Percentile | 0.6% |
| Median | 6.7% |
| 70th Percentile | 13.5% |
| Max | 3 753.7% |
Other Profitability Ratios
PeterLabs Holdings Bhd
Glance View
PeterLabs Holdings Bhd.is an investment company, which engages in the manufacture, distribution and trading of animal health and nutrition products. The company is headquartered in Nilai, Negeri Sembilan. The company went IPO on 2011-07-26. The firm is engaged in the manufacturing, distribution and trading of animal health and nutrition products. Its segments include Manufacturing and Trading. The Manufacturing segment is engaged in the manufacturing of animal health and nutrition products. The Trading segment is engaged in the trading and distribution of animal health and nutrition products. Its products include biosecurity and disinfectant, compound feed supplement, feed additives, nutritional premix, pharmaceutical and water-soluble supplement. The firm provides technical information exchange with its customer’s supervisors, technicians and in-house veterinarians, livestock information sharing, post-mortem on diseased animals, blood sampling of diseased animals for testing and individualize latest technologies in the manufacture of feed additives for feed and farming industry.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for PeterLabs Holdings Bhd is 1.8%, which is below its 3-year median of 2.7%.
Over the last 3 years, PeterLabs Holdings Bhd’s Operating Margin has decreased from 5% to 1.8%. During this period, it reached a low of 1.5% on Dec 31, 2023 and a high of 5% on Jun 30, 2022.